Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer intrinsic protein neddylation modulates the intra-tumoral immune landscape to constrain immune checkpoint blockade therapy.

Cancer immunology research·2026
Same author

High Prevalences of Current Mental Disorder Diagnoses Among University Students in Sweden: A Cross-Sectional Study With Implications for Student Mental Health Services.

International journal of methods in psychiatric research·2026
Same author

Demic diffusion can create chimpanzee gene-cultural linkage.

Journal of human evolution·2026
Same author

An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia.

Communications medicine·2026
Same author

App-based skills training to reduce problem drinking among adult internet help-seekers: a double-blinded randomized controlled trial.

Addiction science & clinical practice·2026
Same author

University students' interest in intervention research participation is associated with gender, age and symptoms of depression, general and social anxiety, panic disorder and self-harm.

BMC research notes·2026

Related Experiment Video

Updated: Feb 19, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Targeting tumor cells based on Phosphodiesterase 3A expression.

Madiha Nazir1, Wojciech Senkowski1, Frida Nyberg1

  • 1Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden.

Experimental Cell Research
|November 7, 2017
PubMed
Summary

Phosphodiesterase 3A (PDE3A) is a promising cancer drug target and biomarker. High PDE3A expression correlates with sensitivity to PDE inhibitors, suggesting its use in personalized cancer therapy.

Keywords:
BiomarkerCancerPDE3ARepositioningTherapy

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.9K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Related Experiment Videos

Last Updated: Feb 19, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.9K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Phosphodiesterase 3A (PDE3A) expression correlates with sensitivity to PDE inhibitors.
  • PDE3A can function as both a drug target and a biomarker for PDE inhibitor sensitivity.

Purpose of the Study:

  • To investigate PDE3A expression in various cancer cell lines and clinical specimens.
  • To determine the correlation between PDE3A expression levels and sensitivity to PDE inhibitors.
  • To explore the relationship between PDE3A and Schlafen family member 12 (SLFN12) expression in clinical samples.

Main Methods:

  • Analysis of publicly available mRNA gene expression data.
  • In vitro sensitivity assays using PDE inhibitors zardaverine and quazinone.
  • Immunofluorescence and immunohistochemical staining for PDE3A protein.
  • Analysis of PDE3A and SLFN12 expression in patient tumor samples (ovarian carcinoma, solid cancers, GIST).

Main Results:

  • Cell lines with high PDE3A mRNA expression exhibited greater sensitivity to PDE inhibitors.
  • Immunofluorescence and immunohistochemistry confirmed PDE3A mRNA expression patterns.
  • Significant variability in PDE3A protein expression was observed in ovarian carcinoma patient tumors.
  • PDE3A was highly expressed in subsets of various solid cancers, notably GIST.
  • High PDE3A mRNA expression in clinical specimens frequently associated with high SLFN12 expression.

Conclusions:

  • PDE3A is a potential predictive biomarker for PDE inhibitor efficacy in cancer treatment.
  • PDE3A represents a viable drug target for developing novel cancer therapies.
  • The co-expression of PDE3A and SLFN12 may further refine patient stratification for PDE inhibitor-based treatments.